August 21, 2017 2:58 AM ET

Pharmaceuticals

Company Overview of Ore Holdings, Inc

Company Overview

Ore Holdings, Inc. focuses on developing and monetizing pharmaceutical assets, including clinical-stage compounds in-licensed from pharmaceutical companies. Its drug candidate portfolio includes ORE1001, an orally-administered small molecule drug for treating inflammatory bowel disease and other gastrointestinal indications; ORE10002, a small molecule serotonergic agent for inflammatory and autoimmune diseases; tiapamil, a small molecule L-type calcium channel antagonist to treat cardiovascular disease, various cognitive disorders, and gastrointestinal indications; and romazarit, a small molecule PPARá agonist for autoimmune, metabolic, inflammatory, and gastrointestinal diseases. The compan...

590 Madison Avenue

New York, NY 10022

United States

Founded in 1994

Phone:

212-520-2260

Key Executives for Ore Holdings, Inc

Ore Holdings, Inc does not have any Key Executives recorded.

Ore Holdings, Inc Key Developments

Ore Holdings Inc. To Be Deleted From Other OTC

Ore Holdings Inc.'s common stock will be deleted from Other OTC, effective August 18, 2017. The deletion was due to Acquisition/Merger/Amalgamation.

Ore Holdings, Inc Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Ore Holdings Inc. announced earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported loss from operations was $73,000 compared with $98,000 a year ago. Net loss before income tax expense was $548,000 compared with $96,000 a year ago. Net loss was $559,000 compared with $96,000 a year ago. Basic and diluted loss per share were $0.01 compared with $0.00 a year ago.

Ore Holdings, Inc Announces Earnings Results for the Three Months Ended March 31, 2017

Ore Holdings Inc. announced earnings results for the three months ended March 31, 2017. For the quarter, the company reported loss from operations was $80,000 compared with $74,000 a year ago. Net income was $1,165,000 compared with loss of $12,000 a year ago. Basic and diluted earnings per share was $0.02 compared with loss of $0.00 a year ago.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 6, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ore Holdings, Inc, please visit www.oreholdings.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.